Efficacy and safety of cladribine, low-dose cytarabine and venetoclax in relapsed/refractory acute myeloid leukemia: results of a pilot study

被引：0
|
作者：
Yan-Yan Li
Shuai-Shuai Ge
Yuan-Hong Huang
Ming-Zhu Xu
Chao-Ling Wan
Kai-Wen Tan
Tao Tao
Hai-Xia Zhou
Sheng-Li Xue
Hai-Ping Dai
机构：
[1] The First Affiliated Hospital of Soochow University,National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology
[2] Soochow University,Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology
[3] The Affiliated Infectious Diseases Hospital of Soochow University,Department of Respiratory and Critical Medicine
来源：
Blood Cancer Journal | / 14卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Efficacy and safety of cladribine, low-dose cytarabine and venetoclax in relapsed/refractory acute myeloid leukemia: results of a pilot study
    Li, Yan-Yan
    Ge, Shuai-Shuai
    Huang, Yuan-Hong
    Xu, Ming-Zhu
    Wan, Chao-Ling
    Tan, Kai-Wen
    Tao, Tao
    Zhou, Hai-Xia
    Xue, Sheng-Li
    Dai, Hai-Ping
    [J]. BLOOD CANCER JOURNAL, 2024, 14 (01)
  • [2] Venetoclax plus Cladribine plus Low-Dose Cytarabine in Acute Myeloid Leukemia Relapsed or Refractory to Venetoclax plus Hypomethylating Agent
    Steinauer, Nickolas
    McCullough, Kristen
    Al-Kali, Aref
    Alkhateeb, Hassan
    Begna, Kebede
    Mangaonkar, Abhishek A.
    Saliba, Antoine
    Hefazi, Mehrdad
    Litzow, Mark R.
    Hogan, William J.
    Shah, Mithun V.
    Pardanani, Animesh D.
    Badar, Talha
    Murthy, Hemant S.
    Foran, James M.
    Yi, Cecilia Y. Arana
    Tefferi, Ayalew
    Gangat, Naseema
    [J]. BLOOD, 2023, 142
  • [3] Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia
    Graveno, Molly E.
    Carulli, Alison
    Freyer, Craig W.
    Mangan, Brendan L.
    Nietupski, Robert
    Loren, Alison W.
    Frey, Noelle, V
    Porter, David L.
    Gill, Saar, I
    Hexner, Elizabeth O.
    Luger, Selina M.
    Martin, Mary Ellen
    McCurdy, Shannon R.
    Perl, Alexander E.
    Babushok, Daria, V
    Pratz, Keith W.
    [J]. LEUKEMIA & LYMPHOMA, 2022, 63 (07) : 1645 - 1650
  • [4] Venetoclax with Hypomethylating Agents or Low-Dose Cytarabine for Relapsed/Refractory Acute Myeloid Leukemia in a Real-Life Setting
    Piccini, Matteo
    Pilerci, Sofia
    Scappini, Barbara
    Bencini, Sara
    Peruzzi, Benedetta
    Caporale, Roberto
    Signori, Leonardo
    Fabiana, Pancani
    Maria, Vannucchi Alessandro
    Gianfaldoni, Giacomo
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S289 - S289
  • [5] Venetoclax, Actinomycin D and Low Dose Cytarabine for Relapsed or Refractory Acute Myeloid Leukemia in Clinical Practice Setting
    Zucenka, Andrius
    Vaitekenaite, Vilmante
    Maneikis, Kazimieras
    Pileckyte, Regina
    Trociukas, Igoris
    Peceliunas, Valdas
    Griskevicius, Laimonas
    [J]. BLOOD, 2021, 138
  • [6] Venetoclax, Cladribine Plus Low-Dose Cytarabine Achieved High Remission in Patients with Relapse/Refractory Acute Leukemia: Preliminary Results of a Phase II Study
    Li, Yanyan
    Zhou, Haixia
    Wan, Chaoling
    Xu, Mingzhu
    Qian, Chongsheng
    Zhang, Tongtong
    Dai, Haiping
    Sun, AiNing
    Wu, Depei
    Xue, Shengli
    [J]. BLOOD, 2022, 140 : 3212 - 3213
  • [7] Venetoclax in Combination with Hypomethylating Agents or Low-Dose Cytarabine for Relapsed/Refractory Acute Myeloid Leukemia: A Retrospective Single-Centre Experience
    Piccini, Matteo
    Pilerci, Sofia
    Scappini, Barbara
    Mannelli, Francesco
    Ciolli, Gaia
    Pasquini, Andrea
    Fasano, Laura
    Quinti, Elisa
    Guglielmelli, Paola
    Mannarelli, Carmela
    Pancani, Fabiana
    Zizza, Michela
    Signori, Leonardo
    Vannucchi, Alessandro M.
    Gianfaldoni, Giacomo
    [J]. BLOOD, 2022, 140 : 9008 - 9009
  • [8] Safety and activity of venetoclax in combination with high-dose cytarabine in children with relapsed or refractory acute myeloid leukemia.
    Karol, Seth E.
    Alexander, Thomas
    Das Gupta, Soumyasri
    Pounds, Stanley B.
    Canavera, Kristin
    Klco, Jeffery M.
    Lacayo, Norman James
    Pui, Ching-Hon
    Opferman, Joseph T.
    Rubnitz, Jeffrey E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [9] Combination of Cladribine, Cytarabine and Topotecan (CLAT) for Relapsed or Refractory Acute Myeloid Leukemia
    Chen, Xiaomei
    Weng, Jianyu
    Wang, Yulian
    Deng, Chengxin
    Luo, Chengwei
    Liao, Pengjun
    Li, Minming
    Huang, Xin
    Lai, Peilong
    Huang, Lisi
    Cao, Zhi
    Wan, Changchun
    Zhong, Liye
    Wu, Suijing
    Lu, Zesheng
    Zou, Xiaoli
    Du, Xin
    [J]. BLOOD, 2015, 126 (23)
  • [10] Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia
    Abboud, Ramzi
    Chendamarai, Ezhilarasi
    Rettig, Michael P.
    Trinkaus, Kathryn M.
    Riedell, Peter A.
    Abboud, Camille N.
    Ghobadi, Armin
    Pusic, Iskra
    Stockerl-Goldstein, Keith
    Schroeder, Mark A.
    Vij, Ravi
    Westervelt, Peter
    DiPersio, John F.
    Uy, Geoffrey L.
    [J]. HAEMATOLOGICA, 2020, 105 (08) : E404 - E407
12345